Evaluation of Cepheid GeneXpert Omni combined...

In the News

Concern over malaria in children with no symptoms

Malaria in children showing no symptoms raises concerns Dar es Salaam. June 16, 2017. ¬†Researchers at Ifakara Health Institute have detected a substantial amount of parasites in children without any …

Call for applications for Bootcamp in Ouagadougou

IHI scientists at a previous bootcamp. PHOTO/COURTESY OF DR. FREDROS OKUMU The Alliance for Accelerating Excellence in Science in Africa (AESA) in collaboration with Ifakara Health Institute and Institut de …

Recent Projects

Understanding and enhancing approaches to quality improvement in small and medium sized private facilities in sub-Saharan Africa

This is an evaluation study that IHI is conducting in collaboration with London school of hygiene and tropical medicine. The research takes place in the context of an innovative intervention …

Vaccine Delivery Costing Study

As countries drive towards achieving high and equitable coverage of life-saving vaccines, the availability of sustainable, equitable, and predictable financing for vaccine delivery is essential. Over the last two decades, …

Cepheid GeneXpert Omni combined with the Xpert MTB/RIF Ultra for detection of tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis at primary-level diagnostic centers in Tanzania: a pragmatic, cluster-randomized controlled trial

GeneXpert Omni (Omni) is a new developed diagnostic tool with characteristic suitable for use in resource limited settings e.g. portability, battery powered. The GeneXpert Omni is considered the next generation of the current existing GeneXpert platform and is developed to address challenges encountered by the current GeneXpert platform in resource limited settings. A new cartridge, Xpert MTB/RIF Ultra (Ultra) has been developed with higher sensitivity approximately similar to culture, the gold standard for tuberculosis (TB) diagnosis. The combination of both Omni and Ultra is expected to impact on important clinical outcomes and hence control TB. The Omni/Ultra trial is pragmatic cluster randomized trial which will evaluate Omni combined with Ultra for TB detection in primary healthcare facilities in Bagamoyo and Dar es Salaam in Tanzania. Fourteen clusters (primary healthcare facilities), seven in each arm, fulfilling inclusion criteria, will be randomized to either the intervention (Omni/Ultra) or remain on standard of care (smear microscopy) for diagnosis of TB. Presumptive TB patients attending selected facilities will undergo diagnostic procedures of TB test using Omni/Ulta or smear microscopy as per randomization arm. Omni/Ultra is planned to recruit 1600 presumptive adult TB patients, who are able to produce sputum. The trial is expected run for 18 months. The primary ends points are;

  • Proportion of participants who have bacteriologically confirmed TB and have TB therapy initiated within 60 days of enrolment
  • Additionally notified TB cases during intervention compared to the standard of care (direct yield)

Omni/Ultra is an investigator initiated trial, implemented by the Ifakara Health Institute in collaboration with the Swiss Tropical and Public Health Institute and the National TB program Tanzania. Omni/Ultra trial is funded by both the STOP TB Partneship|TB REACH initiative and the Foundation for Innovative New Diagnostics.


Swiss Tropical and Public Health Institute


Foundation for Innovative New Diagnostics (FIND) and Stop TB Partnership

Projects Location

© Ifakara Health Institute (IHI), 2016